Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

PURPOSE: Osimertinib is a third-generation, irreversible, oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M and has demonstrated efficacy in non-small cell lung cancer (NSCLC) central nerv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Myung-Ju, Han, Ji-Youn, Kim, Dong-Wan, Cho, Byoung Chul, Kang, Jin-Hyoung, Kim, Sang-We, Yang, James Chih-Hsin, Mitsudomi, Tetsuya, Lee, Jong Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962491/
https://www.ncbi.nlm.nih.gov/pubmed/31345012
http://dx.doi.org/10.4143/crt.2019.200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962491/
https://www.ncbi.nlm.nih.gov/pubmed/31345012
http://dx.doi.org/10.4143/crt.2019.200

Ejemplares similares